<p>Eliquent Life Sciences has joined ExoCordOA, a €13 million, five-year Horizon Europe consortium coordinated by Exogenus Therapeutics that aims to advance extracellular vesicle-enriched secretome therapies toward clinical use, initially targeting osteoarthritis. The program intends to support Phase I</p>